• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate.

作者信息

Killock David

出版信息

Nat Rev Clin Oncol. 2017 Jul;14(7):392. doi: 10.1038/nrclinonc.2017.70. Epub 2017 May 9.

DOI:10.1038/nrclinonc.2017.70
PMID:28485409
Abstract
摘要

相似文献

1
Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate.免疫疗法：纳武单抗可控制肝癌并为战胜癌症开辟途径。
Nat Rev Clin Oncol. 2017 Jul;14(7):392. doi: 10.1038/nrclinonc.2017.70. Epub 2017 May 9.
2
Liver cancer: Nivolumab: checkmate for hepatocellular carcinoma?肝癌：纳武单抗：肝细胞癌的制胜之选？
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):326. doi: 10.1038/nrgastro.2017.62. Epub 2017 May 10.
3
Nivolumab for the treatment of hepatocellular carcinoma.纳武利尤单抗治疗肝细胞癌。
Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22.
4
Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.用于肝细胞癌治疗的免疫刺激单克隆抗体。趋势与展望。
Medicina (B Aires). 2018;78(1):29-32.
5
Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.钇-90放射性栓塞联合PD-1抑制剂治疗晚期肝细胞癌
Cardiovasc Intervent Radiol. 2018 Nov;41(11):1799-1802. doi: 10.1007/s00270-018-1993-1. Epub 2018 May 29.
6
Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature.一名肝细胞癌患者对抗程序性死亡蛋白1（Anti-PD-1）治疗反应良好：病例报告及文献综述
Discov Med. 2017 May;23(128):331-336.
7
Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.肝脏免疫耐受与肝细胞癌：病理生理机制及治疗前景
Eur J Cancer. 2017 Dec;87:101-112. doi: 10.1016/j.ejca.2017.10.010. Epub 2017 Nov 13.
8
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.用于肝细胞癌和病毒性肝炎的特异性CD8(+) T细胞应答免疫疗法。
World J Gastroenterol. 2016 Jul 28;22(28):6469-83. doi: 10.3748/wjg.v22.i28.6469.
9
Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.纳武利尤单抗治疗晚期肝细胞癌的可行性和安全性：来自三个德国中心的真实世界经验。
J Cancer Res Clin Oncol. 2019 Jan;145(1):253-259. doi: 10.1007/s00432-018-2780-8. Epub 2018 Oct 29.
10
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.纳武利尤单抗对比研究者选择的标准单药疗法用于复发性或转移性头颈部鳞状细胞癌（CheckMate 141）：一项随机3期试验的健康相关生活质量结果
Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

引用本文的文献

1
Identification of a Novel Prognostic Signature Based on N-Linked Glycosylation and Its Correlation with Immunotherapy Response in Hepatocellular Carcinoma.基于N-糖基化的肝细胞癌新型预后标志物的鉴定及其与免疫治疗反应的相关性
J Hepatocell Carcinoma. 2023 Oct 9;10:1749-1765. doi: 10.2147/JHC.S417407. eCollection 2023.
2
Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment.CKS2在肝细胞癌中的表达：与生存结果及免疫微环境的相关性
J Hepatocell Carcinoma. 2023 Oct 9;10:1767-1784. doi: 10.2147/JHC.S427624. eCollection 2023.
3
Hepatocellular Carcinoma Genetic Classification.

本文引用的文献

1
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
肝细胞癌的遗传学分类。
Cancer J. 2023;29(5):249-258. doi: 10.1097/PPO.0000000000000682.
4
Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma.肝细胞癌中与铁死亡相关基因FANCD2的预后、肿瘤免疫及ceRNA网络的综合分析
Front Genet. 2022 Sep 29;13:955225. doi: 10.3389/fgene.2022.955225. eCollection 2022.
5
Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy.肝细胞癌中增强子RNA的综合表征揭示了三种免疫亚型及其对免疫治疗的意义。
Mol Ther Oncolytics. 2022 Jul 6;26:226-244. doi: 10.1016/j.omto.2022.07.001. eCollection 2022 Sep 15.
6
Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.肝细胞癌 (HCC)：基于肿瘤生物学特征，在临床前领域最有希望的治疗靶点。
Expert Opin Ther Targets. 2021 Aug;25(8):645-658. doi: 10.1080/14728222.2021.1976142. Epub 2021 Sep 11.
7
IFN-α facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma.干扰素-α通过改变肝癌中肿瘤相关巨噬细胞的M2样极化来增强索拉非尼的疗效。
Am J Transl Res. 2021 Jan 15;13(1):301-313. eCollection 2021.
8
Annexin A2 promotion of hepatocellular carcinoma tumorigenesis the immune microenvironment.膜联蛋白 A2 促进肝细胞癌肿瘤发生的免疫微环境。
World J Gastroenterol. 2020 May 14;26(18):2126-2137. doi: 10.3748/wjg.v26.i18.2126.
9
Metabolism-associated molecular classification of hepatocellular carcinoma.肝细胞癌的代谢相关分子分类。
Mol Oncol. 2020 Apr;14(4):896-913. doi: 10.1002/1878-0261.12639. Epub 2020 Jan 29.
10
Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.细胞周期蛋白依赖性激酶调节亚基 2 预示着肝癌不良预后并促进其侵袭性表型。
Dis Markers. 2019 Oct 22;2019:8964015. doi: 10.1155/2019/8964015. eCollection 2019.